A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.
Breast Neoplasms
DRUG: docetaxel|DRUG: PF-3512676
Progression-free survival|Tumor assessment every 6 weeks until disease progression
Overall objective response rate, duration of response, time to tumor progression - tumor assessment every 6 weeks until disease progression|Overall Survival - Patients will be followed for survival|Overall safety profile -Targeted questions to patients throughout study, Weekly blood sampling during treatment, every 3 weeks during follow-up, Urine sample every 3 weeks during treatment and follow-up|Changes in pain symptoms -Brief Pain Inventory questionnaire every 3 weeks during chemotherapy
To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.